Kiai Parsa purchased $1.1M of MED (indirect holdings)

Kiai Parsa purchased 94,036 indirectly-held shares of MEDIFAST INC (MED) at an average of $12.06 ($12.05–$12.16, $1.13M total) across 4 trades over 2026-11-18 to 2026-11-19.

Original reporting
SEC EDGAR · Kiai Parsa
Published Nov 20, 2026, 7:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 20, 2026, 7:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MED
Bullish
medium confidence
Mentioned
$MED
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MEDBullishLow
01

Why it matters

Traders may briefly re-rate sentiment based on insider accumulation, but the filing does not introduce new operating, financial, or strategic information.

02

Market read

A director’s $1.13M indirect purchase is a modest sentiment input, but it is not a standalone fundamental catalyst.

03

What to watch

The filing does not provide rationale, and the price range ($12.0464 to $12.1613) suggests execution near prevailing market levels, limiting inference about near-term fundamentals.

Relevance 7/10Novelty 6/10Timing: SEC Form 4 filed 2026-11-20, reflecting trades dated 2026-11-18 to 2026-11-19.

Background

The article is an SEC Form 4 insider transaction disclosure for Medifast, Inc., reported by director Kiai Parsa with indirect holdings.

Company-level read

Ticker impact

$MEDBullishMedium confidence
Context

Director Kiai Parsa bought $1.13M of MED via indirect holdings, filing a Form 4 for 94,036 shares at about $12.06 weighted average.

Expected impact

Likely mild upward bias as traders note insider accumulation, with limited follow-through absent other company-specific news.

Evidence & confidence

The disclosure is a primary SEC Form 4, but the transaction is an insider purchase without accompanying guidance, deal, or operational change.

Market effects

Minimal, as this is single-company insider activity with no sector-wide operational or regulatory change.

None indicated.

None indicated.

Counterpoint

Because the purchase is indirect and not under a 10b5-1 plan, it may reflect personal liquidity or tax/estate structuring rather than a strong forward-looking view.

Key entities

  • MEDIFAST INC

    US-listed issuer referenced in the Form 4 insider transaction.

  • Kiai Parsa

    Director who purchased MED shares via indirect holdings.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MEDMed

5 insightful analyst questions from Medifast’s Q3 earnings call

Medifast's Q3 revenue exceeded expectations but declined year-over-year. Management cited the Trilogy brand's success and improved coach productivity. Analysts questioned coach engagement, competition with GLP-1 medications, and cost reduction. The stock is trading at $12.50. Key focus areas include Trilogy adoption, coach productivity, and cost efficiencies.

$MEDHigh

Why Medifast (MED) stock is trading up today

Medifast (MED) shares rose 6.2% after Q3 results beat expectations, with adjusted EBITDA of $1.9M. CEO Nick Johnson highlighted new product launches and guidance for Q4 revenue of $55M-$75M. Full-year revenue is expected at $280M-$300M, with a GAAP loss of $1.80-$2.05 per share.

$MEDMed

Medifast Inc (MED) (Q3 2026) Earnings Call Highlights: Revenue Stabilizes Near $75 Million

Medifast Inc (MED) reported Q3 2026 revenue of $72M, down 19.4% YoY, with revenue stabilizing near $75M for four quarters. CEO Nicholas Johnson highlighted high engagement and productivity among coaches, despite a decline in active coach numbers. The company expects continued productivity growth and cost efficiencies. Q4 revenue guidance is $55M-$75M, with EPS of $0-$0.25. Medifast has $172.5M in cash and no debt, with a target of profitability in Q4 2026.

$MEDMed

Medifast, Inc. Q3 2026 Earnings Call Summary

Medifast (MED) reported a 19.4% revenue decline in Q3 2026, attributing it to lower active coach counts due to GLP-1 medication adoption. The company is transitioning to a metabolic health system called Trilogy and implementing cost-cutting measures. Q4 2026 revenue is expected between $55M and $75M, with a focus on profitability and long-term growth. Management sees GLP-1s as a catalyst for consumer interest rather than a direct threat.

$MEDMed

What Medifast (MED) Said on Its Q3 Earnings Call

Medifast (MED) reported a Q3 operating loss of $19.4M, including restructuring charges. The company introduced new products and highlighted GLP-1 medications' impact on client conversations. Medifast forecasts Q4 revenue of $55M-$75M and full-year 2026 revenue of $280M-$300M, aiming for profitability in Q4.